Tau PET in Imaging and Cognition: Healthy Adults From 55-90

Recruiting now

Conditions studied: Mild Cognitive Impairment, Aging

In brief

The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.

Key facts

Study ID

NCT03372317

Run by

Yaakov Stern

People needed

105

Starts

2018-06-01

Expected to finish

2027-12-01

Last updated by the study team

2026-02-11

Who can join

Age: 55 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Aged 55-90
• Previously received an amyloid PET scan
• Residing near Columbia University Medical Center
• Must be willing and able to participate

You may not qualify if…

• Have a contraindication to PET (e.g, metallic implants, pacemaker, claustrophobia, or cannot lie flat for one hour)
• Pregnancy
• Lactating Women
• Current, past, or anticipated exposure to radiation
• Significant active physical illness

Where it is running

• Columbia University Medical Center — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.